Fig. 2From: Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case reportClinical course of the patient. R-CP indicates immunochemotherapy with rituximab, cyclophosphamide and prednisolone; sIL2R, soluble interleukin 2 receptor; IgG4, immunoglobulin G4; EBV, Epstein-Barr virusBack to article page